undamentalytics Newsletter
Sign in

Bionexus Gene Lab Corp (BGLC) stock

Add to watchlist

Add holding +

NASDAQ: BGLC Nasdaq Life Sciences Tools & Services

E Fundamentals grade

Bionexus Gene Lab Corp is a US-listed company in the life sciences tools & services industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$1.8

Price-to-sales vs peers

Base case. Range ~$1.8–$8.6. Sales per share times peers' typical price-to-sales; used only when earnings are negative.

Price vs value

No Buy/Hold/Sell rating is issued: only 1 valuation models apply; a rating needs 3.

Bionexus Gene Lab Corp valuation: adjust assumptions and compare models →

Value diary

Our note on each quarter Bionexus Gene Lab files

Where Bionexus Gene Lab stands after its latest 10-Q

Bionexus Gene Lab has little or no product revenue yet; it used $1m of cash in the twelve months to June 2026. That puts it 46 of 47 for growth among the life sciences tools & services companies we cover. Against its peers on growth, profitability, cash generation and balance sheet, it grades E. It passes 2 of our 2 financial-health checks. Our price-to-sales vs peers value is $2.89 a share, against a share price of $0.92.

Source: 10-Q filed August 14, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Bionexus Gene Lab Corp's trailing-twelve-month revenue fell 67.3% year on year, with a free-cash-flow margin of -27.3%. Where it lags: revenue growth of -67.3% ranks 53 of 54 life sciences tools & services companies we cover.

Current signal Revenue growth decelerating: TTM revenue growth slowed to -67.3% (-24.6pp vs the prior quarter), the 4th consecutive quarterly slowdown.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Net cash. Cash exceeds long-term debt by $0.0bn.

Things to watch

  • Revenue shrinking. Revenue fell 67.3% over the last 12 months.
  • Growth slowing. The growth rate is 24.6 points lower than a quarter earlier.
  • Loss-making. Operating margin is -81.8%: costs exceed revenue.
  • Margins narrowing. Operating margin is down 50.6 points on a year ago.
  • Burning cash. Free cash flow was -27.3% of revenue over the last 12 months.
  • Volatile shares. Over the past year the shares showed annualised volatility of 69% and a beta of 1.4 against the S&P 500.

Latest results: FY2026 Q2

Filed August 14, 2026
Revenue
$0m, down 96.6% on a year earlier

Bionexus Gene Lab's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+9.5%
  • 1 week-13.4%
  • 1 month-20.9%
  • This year-74.6%
  • 1 year-81.5%
  • 5 years-99.6%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$3.1M
Operating margin
-81.8%
Net margin
-82.4%

Growth

Revenue growth
−67.3%
Change in growth rate
−24.6 pts

Cash

Free cash flow (TTM)
-$853,600
FCF margin
-27.3%

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Agreement
  2. Announcement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Bionexus Gene Lab Corp valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: only 1 valuation models apply; a rating needs 3.

Valuation models

We value Bionexus Gene Lab Corp as an operating company, with every model that fits that kind of business. Cost of equity 8.3%: the 10-year Treasury yield (4.9%) plus a beta of 0.73 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. ~$1.8 ~$2.4–$8.6 Included, half weight
Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$1.8 ~$1.8–$8.6 1 model

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Bionexus Gene Lab Corp with Life Sciences Tools & Services in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20232024
Share price$5.30$2.80
Market value$84m$50m
+ Net debt (− = net cash)−$5m−$3m
Enterprise value$80m$47m
Multiples
Price / sales 8.6x5.2x
Price / earnings ——
Price / free cash flow ——
EV / EBITDA ——

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

23 /100

Weak moat

How hard Bionexus Gene Lab's competitive advantage looks for rivals to wear away, judged from 8 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -12.9% of total assets over 8 years.

  • Pricing power 7 / 20

    Gross margin has been a median 14.2%, moving by 2.8 percentage points (standard deviation) across 8 years.

  • Durability 10 / 20

    Operating margin has been a median -13.8%; its worst year was -164.4%.

  • Cash conversion 5 / 20

    Free cash flow was positive in 4 of 8 years, at a median -11.9% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (28 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

No analyst estimates are published for Bionexus Gene Lab Corp: too few analysts cover it.

Positioning

Short interest
0.4%
of tradable shares
Days to cover
0.92
at average volume
Short interest, 1 month
−31%
to October 15, 2026
Held by institutions
0%
of shares
Held by insiders
44.7%
of shares
Employees
19
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months −81.5%

$5.42 on October 31, 2025 to $1.00

ThenNowEffect
Revenue (last 12 months) $10m $3m −67.3%
P/S multiple 1.0x 0.7x −33.3%
Share count 2m 2m −15.1%

Biggest factor: revenue. Loss-making at one end, so the split uses price/sales.

Last 3 years −75.4%

$4.09 on November 3, 2023 to $1.00

ThenNowEffect
Revenue (last 12 months) $10m $3m −69.8%
P/S multiple 0.6x 0.7x +11.2%
Share count 2m 2m −26.8%

Biggest factor: revenue. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 20222023202420252026 to date
Return
BGLC−55%−95%−47%+41%−75%
Industry peers (median)−51%−3%−13%−7%+16%
S&P 500−18%+26%+25%+18%+11%
Months that ended higher
BGLC25%25%50%33%36%
S&P 50042%67%75%75%46%
Largest fall from a high during the year
BGLC−68%−98%−85%−66%−77%
S&P 500−25%−10%−8%−19%−9%

Worst fall since January 8, 2021: 100% from March 3, 2021 to October 30, 2026. Getting back needed a 31011% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$0.92 – $5.48
From 52-week high
−81.7%
vs 50-day average
−24.9%
vs 200-day average
−48.4%
Volatility (1 year)
69%
Beta vs S&P 500
1.42

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Fundamentals

Revenue (TTM) Bionexus Gene Lab Corp
$0 $5M $10M $15M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $10.3M Revenue (TTM), FY23 Q4: $9.8M Revenue (TTM), FY24 Q1: $9.8M Revenue (TTM), FY24 Q2: $9.2M Revenue (TTM), FY24 Q3: $9.3M Revenue (TTM), FY24 Q4: $9.5M Revenue (TTM), FY25 Q1: $9.3M Revenue (TTM), FY25 Q2: $9.6M Revenue (TTM), FY25 Q3: $9.5M Revenue (TTM), FY25 Q4: $7.4M Revenue (TTM), FY26 Q1: $5.3M Revenue (TTM), FY26 Q2: $3.1M $3.1M

Source: SEC EDGAR filings. Retrieved October 31, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $10.3M
FY23 Q4 $9.8M
FY24 Q1 $9.8M
FY24 Q2 $9.2M
FY24 Q3 $9.3M
FY24 Q4 $9.5M
FY25 Q1 $9.3M
FY25 Q2 $9.6M
FY25 Q3 $9.5M
FY25 Q4 $7.4M
FY26 Q1 $5.3M
FY26 Q2 $3.1M
Revenue growth, TTM YoY Bionexus Gene Lab Corp
-80% -60% -40% -20% 0% 20% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: -8.8% Revenue growth, TTM YoY, FY23 Q4: -10.6% Revenue growth, TTM YoY, FY24 Q1: -4.9% Revenue growth, TTM YoY, FY24 Q2: -11.3% Revenue growth, TTM YoY, FY24 Q3: -10.4% Revenue growth, TTM YoY, FY24 Q4: -2.7% Revenue growth, TTM YoY, FY25 Q1: -5.2% Revenue growth, TTM YoY, FY25 Q2: 4.0% Revenue growth, TTM YoY, FY25 Q3: 2.2% Revenue growth, TTM YoY, FY25 Q4: -21.9% Revenue growth, TTM YoY, FY26 Q1: -42.7% Revenue growth, TTM YoY, FY26 Q2: -67.3% -67.3%

Source: SEC EDGAR filings. Retrieved October 31, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 -8.8%
FY23 Q4 -10.6%
FY24 Q1 -4.9%
FY24 Q2 -11.3%
FY24 Q3 -10.4%
FY24 Q4 -2.7%
FY25 Q1 -5.2%
FY25 Q2 4.0%
FY25 Q3 2.2%
FY25 Q4 -21.9%
FY26 Q1 -42.7%
FY26 Q2 -67.3%
Operating margin (TTM) Bionexus Gene Lab Corp
-100% -50% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -28.8% Operating margin (TTM), FY23 Q4: -26.5% Operating margin (TTM), FY24 Q1: -26.8% Operating margin (TTM), FY24 Q2: -22.8% Operating margin (TTM), FY24 Q3: -9.7% Operating margin (TTM), FY24 Q4: -16.5% Operating margin (TTM), FY25 Q1: -22.8% Operating margin (TTM), FY25 Q2: -31.2% Operating margin (TTM), FY25 Q3: -24.8% Operating margin (TTM), FY25 Q4: -39.9% Operating margin (TTM), FY26 Q1: -54.4% Operating margin (TTM), FY26 Q2: -81.8% -81.8%

Source: SEC EDGAR filings. Retrieved October 31, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -28.8%
FY23 Q4 -26.5%
FY24 Q1 -26.8%
FY24 Q2 -22.8%
FY24 Q3 -9.7%
FY24 Q4 -16.5%
FY25 Q1 -22.8%
FY25 Q2 -31.2%
FY25 Q3 -24.8%
FY25 Q4 -39.9%
FY26 Q1 -54.4%
FY26 Q2 -81.8%
FCF margin (TTM) Bionexus Gene Lab Corp
-40% -30% -20% -10% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -6.5% FCF margin (TTM), FY23 Q4: -20.2% FCF margin (TTM), FY24 Q1: -19.6% FCF margin (TTM), FY24 Q2: -27.8% FCF margin (TTM), FY24 Q3: -35.8% FCF margin (TTM), FY24 Q4: -24.4% FCF margin (TTM), FY25 Q1: -33.4% FCF margin (TTM), FY25 Q2: -33.3% FCF margin (TTM), FY25 Q3: -27.7% FCF margin (TTM), FY25 Q4: -25.3% FCF margin (TTM), FY26 Q1: -22.4% FCF margin (TTM), FY26 Q2: -27.3% -27.3%

Source: SEC EDGAR filings. Retrieved October 31, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -6.5%
FY23 Q4 -20.2%
FY24 Q1 -19.6%
FY24 Q2 -27.8%
FY24 Q3 -35.8%
FY24 Q4 -24.4%
FY25 Q1 -33.4%
FY25 Q2 -33.3%
FY25 Q3 -27.7%
FY25 Q4 -25.3%
FY26 Q1 -22.4%
FY26 Q2 -27.3%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q, 10-Q/A. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 0 0 11 13 11 10 10 7 3
Gross profit 0 0 2 2 1 1 1 1 0
EBITDA 0 −0 1 1 −0 −3 −1 −3 −2
Operating income 0 −0 1 1 −0 −3 −2 −3 −3
Net income 0 −0 1 1 −0 −3 −2 −3 −3
Diluted EPS $0.00 $0.00 $0.12 — — −$0.17 −$0.09 — —
Growth (year on year)
Revenue — −40.2% +>999% +17.3% −18.2% −10.6% −2.7% −21.9% −67.3%
EBITDA — −332.8% — −15.9% −117.4% — — — —
Operating income — −560.3% — −17.1% −127.6% — — — —
Net income — <−999% — −31.3% −147.4% — — — —
Margins
Gross margin 13.5% 44.0% 15.1% 17.0% 11.5% 13.6% 13.6% 14.6% 12.3%
EBITDA margin 47.3% −184.3% 12.0% 8.6% −1.8% −25.7% −15.5% −38.4% −78.2%
Operating margin 28.2% −217.2% 11.2% 7.9% −2.7% −26.5% −16.5% −39.9% −81.8%
Net margin 12.5% −194.1% 9.6% 5.6% −3.3% −26.9% −16.8% −40.2% −82.4%
Free-cash-flow margin −110.4% −181.2% 1.2% 0.0% 5.0% −20.2% −24.4% −25.3% −27.3%
Cash flow
Cash from operations −0 −0 1 0 1 −2 −2 −2 −1
Capital spending −0 0 0 0 0 0 0 0 0
Free cash flow −0 −0 0 0 1 −2 −2 −2 −1
Stock-based pay — — — — 0 1 0 1 —
Free cash flow after stock pay — — — — 1 −2 −2 −3 —
Balance sheet
Cash 1 1 3 2 2 5 3 2 1
Total debt 0 0 0 0 0 0 0 0 0
Net debt (negative = net cash) −1 −1 −3 −2 −2 −5 −3 −2 −1
Diluted shares 7m 9m 10m — — 16m 18m — —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 2 checks passed · June 30, 2026
What it owns · $9m
Short-term assets $5mLonger-term assets $4m
What it owes, and who funded it · $9m
Short-term liabilities $1mLonger-term liabilities $0mShareholders' equity $8m
  • Short-term assets cover short-term liabilities $5m of assets due within a year against $812,938 of liabilities due within a year.
  • Short-term assets cover long-term liabilities $5m short-term assets against $135,043 of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Bionexus Gene Lab Corp's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

R&D spending
1.7%
of revenue

Competitors: side by side with peers

Closest by revenue in life sciences tools & services
Last 12 months unless stated BGLC QSI SEER YDES ISPC BNGO Median
Revenue, last 12 months $3m $2m $14m $596817 $466302 $30m $229m
Revenue growth, last 12 months −67.3% −53.0% −12.7% 16.9% −92.1% 10.0% 6.9%
Revenue growth, 3-year average −32.9% 51.8% −5.1% — −64.1% −1.4% 2.9%
Revenue growth, latest quarter −96.6% −41.8% −23.4% — −78.7% 21.4% 8.5%
Gross margin 12.3% 35.0% 47.7% 28.1% −98.0% 47.5% 51.9%
Operating margin −81.8% <−999% −498.2% −883.3% <−999% −106.7% −14.3%
Operating margin, 3-year average −45.3% <−999% −575.4% — −768.0% −293.0% −22.4%
Net margin −82.4% <−999% −478.0% <−999% <−999% −106.6% −16.1%
Cash from operations / revenue −27.1% <−999% −305.1% <−999% <−999% −67.9% 1.3%
Free-cash-flow margin −27.3% <−999% −311.1% <−999% <−999% −67.9% −2.2%
Free-cash-flow margin, 3-year average −29.5% <−999% −335.4% — −549.8% −150.1% 0.6%
Stock pay / revenue — 693.5% 74.3% 75.1% 1.0% 11.6% 4.4%
Change in share count — 31.2% 0.2% 3.1% — — 1.0%

Median of all 54 companies we cover in life sciences tools & services. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

54 life sciences tools & services companies
Measure Company Peer median Rank
Revenue growth Growth -67.3% 6.9% 53 of 54
Change in growth rate Growth -24.6pp +0.4pp 53 of 54
Gross margin Profitability 12.3% 52.0% 44 of 45
Operating margin Profitability -81.8% -14.3% 39 of 52
Net margin Profitability -82.4% -12.2% 42 of 54
Free-cash-flow margin Cash generation -27.3% -1.3% 40 of 54

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Geography
Region Revenue Share YoY
Malaysia $5.8M 78.5% ▼ 21.8%
MV $680,994 9.2% ▼ 10.6%
LK $452,639 6.1% ▼ 1.4%
Singapore $240,757 3.2% ▼ 57.9%
ID $114,867 1.5% ▼ 16.9%
BD $106,253 1.4% ▼ 13.8%

From Bionexus Gene Lab Corp's 10-K filed April 14, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

13F filings for June 30, 2026
Reported value
$27,199
Institutions reporting
3
Shares held vs prior quarter
▲ 6100.4%
Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
HRT Financial LP $27,000 14K 99.3% New
UBS Group AG $197 0K 0.7% ▼ 56.3%
Caitong International Asset Management Co., Ltd $2 0K 0.0% New

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Bionexus Gene Lab Corp's complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $0 net buying

No open-market insider trades reported in the last 12 months.

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Recent SEC filings

Data status

When each part of this page on Bionexus Gene Lab Corp was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Bionexus Gene Lab Corp in brief

What does Bionexus Gene Lab Corp do?
Bionexus Gene Lab Corp is a US-listed company in the life sciences tools & services industry. Its financial year ends in December.
What is Bionexus Gene Lab Corp's stock ticker?
Bionexus Gene Lab Corp trades under the ticker BGLC on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Bionexus Gene Lab Corp's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Bionexus Gene Lab Corp reported revenue of $3.1M, 67.3% lower than a year earlier, according to its SEC filings.
What is Bionexus Gene Lab Corp's free cash flow?
Bionexus Gene Lab Corp's free-cash-flow margin is -27.3% of revenue over the trailing twelve months, ranking 40 of the 54 life sciences tools & services companies we cover.
Who are Bionexus Gene Lab Corp's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are HRT Financial LP, UBS Group AG and Caitong International Asset Management Co., Ltd. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Bionexus Gene Lab Corp's market cap?
On December 31, 2024, Bionexus Gene Lab Corp's market capitalisation was about $49.9M and net debt of -$2.9M. Market figures come from third-party market data and may be delayed.
Who are Bionexus Gene Lab Corp's competitors?
In our Life Sciences Tools & Services peer group, the companies closest to Bionexus Gene Lab Corp are Quantum-si Inc, Seer, Inc., YD Bio Ltd, Ispecimen Inc. and Bionano Genomics, Inc. The side-by-side comparison below sets their revenue, margins and growth against Bionexus Gene Lab Corp's.